Safety and Clinical Outcomes of Insulin Degludec in Korean Patients with Diabetes in Real-World Practices: A Prospective, Observational Study
ConclusionIn real-world clinical practice, 26 weeks of IDeg treatment resulted in significant reductions in glycemic parameters with a low incidence of AEs in Korean patients with diabetes. No new safety signals were observed.Clinical Trials Registry and Registration NumberThis trial is registered under ClinicalTrials.gov (NCT02779413) and the universal trial number is [U1111-1176-2287]. (Source: Diabetes Therapy)
Source: Diabetes Therapy - July 19, 2023 Category: Endocrinology Source Type: research
Treatment Burden on Once-Weekly Omarigliptin Versus Daily Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes: Randomized Controlled Trial (ONWARD-DPP4 Study)
ConclusionAlthough this study failed to demonstrate the improvement of DTBQ total score by switching from daily DPP4is to omarigliptin compared with continuing the daily DPP4is, the DTBQ subscale score implementation and flexibility burden score were significantly improved only in the group that switched to omarigliptin, suggesting the possibility of switching from daily DPP4is to omarigliptin to decrease the patients ’ medication burden.Trial RegistrationjRCTs031200437. (Source: Diabetes Therapy)
Source: Diabetes Therapy - July 19, 2023 Category: Endocrinology Source Type: research
Sex Hormone Binding Globulin is an Independent Predictor for Insulin Resistance in Male Patients with Newly Diagnosed Type 2 Diabetes Mellitus
ConclusionsSHBG is an independent predictor for insulin resistance in male patients with newly diagnosed T2DM.Trial Registration NumberKY20220314-01. (Source: Diabetes Therapy)
Source: Diabetes Therapy - July 18, 2023 Category: Endocrinology Source Type: research
Fast-Acting Insulin Aspart in Patients with Type 1 Diabetes in Real-World Clinical Practice: A Noninterventional, Retrospective Chart and Database Study
ConclusionsSwitching to faster aspart was associated with improvements in glycemic control without increasing hypoglycemia in adults with T1D using MDI in this real-world setting. (Source: Diabetes Therapy)
Source: Diabetes Therapy - July 14, 2023 Category: Endocrinology Source Type: research
External Validation of the BRAVO Diabetes Model Using the EXSCEL Clinical Trial Data
ConclusionsThis study demonstrates the feasibility of using the BRAVO model in settings where only fully de-identified patient-level data are available. (Source: Diabetes Therapy)
Source: Diabetes Therapy - July 11, 2023 Category: Endocrinology Source Type: research
Prevalence of Diabetic Kidney Disease with Different Subtypes in Hospitalized Patients with Diabetes and Correlation Between eGFR and LncRNA XIST Expression in PBMCs
ConclusionsOur study revealed that 39.9% of DM inpatients who were admitted to the hospital had DKD. Importantly, lncRNA XIST expression in PBMCs of female patients with DKD was significantly correlated with eGFR and HbA1c. (Source: Diabetes Therapy)
Source: Diabetes Therapy - July 9, 2023 Category: Endocrinology Source Type: research
Prevalence of Positivity for Diabetes-Associated Autoantibodies in Individuals with Type 2 Diabetes and Their Further Characterisation: Cross-sectional Study from Slovakia
ConclusionSeveral pathological processes linked with distinct types of diabetes can develop in parallel, including insulin resistance and autoimmune insulitis. In this single-centre cross-sectional study from Slovakia, we report a higher than previously published prevalence of DAA positivity in a group of individuals with a formal diagnosis of T2D. (Source: Diabetes Therapy)
Source: Diabetes Therapy - July 8, 2023 Category: Endocrinology Source Type: research
Overall Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitor Luseogliflozin Versus Dipeptidyl-Peptidase 4 Inhibitors: Multicenter, Open-Label, Randomized-Controlled Trial (J-SELECT study)
ConclusionThis study showed the overall efficacy of luseogliflozin compared with DPP-4is over the mid/long term, regardless of BMI or age. The results suggest the importance of assessing multiple aspects regarding the effects of diabetes management.Trial Registration NumberjRCTs031180241. (Source: Diabetes Therapy)
Source: Diabetes Therapy - July 6, 2023 Category: Endocrinology Source Type: research
Switching from Multiple Insulin Injections to a Fixed Combination of Degludec and Liraglutide in Patients with Type 2 Diabetes Mellitus: Results from the Simplify Study After 6 Months
ConclusionThe results of this study suggest that switching from BBIT to IDegLira in patients with T2DM and preserved insulin secretion can simplify treatment without compromising glycemic control. The switch to IDegLira was associated with significant improvements in various glucose control parameters, including HbA1c, glycemic profile, hypoglycemia, insulin doses, and CGM-derived parameters TIR and TAR. Additionally, it led to significant reductions in body weight, blood pressure, lipid profile, and liver enzyme levels. Switching to IDegLira may be considered a safe and beneficial approach in clinical practice settings, o...
Source: Diabetes Therapy - July 4, 2023 Category: Endocrinology Source Type: research
